Publications by authors named "Ruao Chen"
Article Synopsis
- Thymic neuroendocrine tumors (Th-NETs) are rare, aggressive cancers, and this study aimed to evaluate how prognostic markers and TMZ-based chemotherapy affect patient survival.
- The research involved reviewing records of 32 patients diagnosed with Th-NETs from 2013 to 2023, highlighting median progression-free survival of 12.5 months for those on TMZ and 51.0 months for surgical patients.
- Key findings showed that the neutrophil-to-lymphocyte ratio (NLR) is a vital prognostic indicator, while high Ki67 levels and lack of surgery correlate with worse survival outcomes; suggesting that surgical treatment remains the primary therapy, with further focus needed on specific biomarkers.
Background: Type 1 gastric neuroendocrine tumors (NETs) are relatively rare to the extent that some physicians have little experience in diagnosing and treating them. The purpose of this study was to increase the understanding of the disease by analyzing and summarizing the management and prognoses of patients with type 1 gastric NETs at our center.
Methods: The data of 229 patients (59.
Introduction: Treatment response to the standard therapy is low for metastatic pancreatic neuroendocrine tumors (PanNETs) mainly due to the tumor heterogeneity. We investigated the heterogeneity between primary PanNETs and metastases to improve the precise treatment.
Methods: The genomic and transcriptomic data of PanNETs were retrieved from the Genomics, Evidence, Neoplasia, Information, Exchange (GENIE), and Gene Expression Omnibus (GEO) database, respectively.
The genetic characteristics of rectal neuroendocrine tumors (R-NETs) were poorly understood. Depicting the genetic characteristics may provide a biological basis for prognosis prediction and novel treatment development. Tissues of 18 R-NET patients were analyzed using whole-exome sequencing.
View Article and Find Full Text PDF